Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Equity Average (2016 - 2025)

Catalyst Pharmaceuticals' Equity Average history spans 15 years, with the latest figure at $937.3 million for Q4 2025.

  • For Q4 2025, Equity Average rose 35.0% year-over-year to $937.3 million; the TTM value through Dec 2025 reached $937.3 million, up 35.0%, while the annual FY2025 figure was $841.0 million, 50.77% up from the prior year.
  • Equity Average reached $937.3 million in Q4 2025 per CPRX's latest filing, up from $888.1 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $937.3 million in Q4 2025 to a low of $174.1 million in Q1 2021.
  • Average Equity Average over 5 years is $447.1 million, with a median of $358.2 million recorded in 2023.
  • Peak YoY movement for Equity Average: rose 22.63% in 2022, then skyrocketed 88.55% in 2024.
  • A 5-year view of Equity Average shows it stood at $202.7 million in 2021, then soared by 40.68% to $285.2 million in 2022, then rose by 29.09% to $368.2 million in 2023, then surged by 88.55% to $694.3 million in 2024, then surged by 35.0% to $937.3 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Equity Average are $937.3 million (Q4 2025), $888.1 million (Q3 2025), and $825.2 million (Q2 2025).